Gilead's Weekly HIV Pill Was Supposed to Change Everything. Then It Backfired.

For Gilead, this isn't just a clinical setback. It's a strategic one. The company has spent years positioning lenacapavir as the backbone of its next-generation HIV franchise. Losing a key oral formulation forces a recalibration of how quickly that vision materializes.

Why This Stings More Than Most Pipeline Failures

Let's zoom out for a second. Gilead isn't some scrappy startup hoping for a lucky break. Its HIV franchise generated $20.8 billion in product sales in 2025, up 6% year over year. Biktarvy alone brought in approximately $15.4 billion. The company commands more than 50% of the global HIV treatment market and over 52% in the U.S.

So this isn't an existential crisis. But it is a meaningful dent in Gilead's carefully choreographed pipeline narrative. CEO Daniel O'Day highlighted seven pipeline candidates at the JPM Healthcare Conference in January 2026, emphasizing dosing flexibility across oral and injectable formats. The weekly oral pill was supposed to be a crown jewel.

The termination also raises a broader, uncomfortable question: how feasible are long-acting oral HIV treatments in general? Injectable long-acting options (like ViiV Healthcare's cabotegravir/rilpivirine, given monthly or every two months) have proven the concept works. But cramming enough drug into a single weekly pill to maintain therapeutic levels for seven days, without toxic side effects, is a fundamentally harder pharmacological problem. Gilead just learned that the hard way.

The Pipeline Is Bruised, Not Broken

Before anyone writes Gilead's HIV obituary, though, the company still has a deep bench. Several lenacapavir-based programs remain very much alive:

The daily option: Phase 3 ARTISTRY trials showed that a bictegravir/lenacapavir single-tablet regimen maintained viral suppression in treatment-experienced patients. Regulatory filings are expected.

The weekly option (take two): Gilead is collaborating with Merck on an islatravir/lenacapavir weekly oral combo. Phase 2 data at 96 weeks showed viral suppression, and Phase 3 ISLEND trials are underway. This is now the weekly horse Gilead is betting on.

The injectables: A twice-yearly lenacapavir injection for PrEP (pre-exposure prophylaxis, or preventive treatment for people at risk of HIV) has confirmed safety and efficacy through the PURPOSE program. Gilead has partnered with PEPFAR and the Global Fund to reach up to 2 million people in low- and middle-income countries.

The moonshot: Phase 1 data suggest a once-yearly lenacapavir formulation could maintain effective drug concentrations for over 56 weeks. Gilead is advancing directly to Phase 3. One shot per year. Let that sink in.

The company projects 6% HIV revenue growth in 2026, with total product sales guided at $29.6 to $30.0 billion. Yeztugo (the branded name for lenacapavir in prevention) pulled in $150 million in its launch year and is projected to hit roughly $800 million in 2026.

The Bigger Picture

No approved long-acting oral HIV treatment exists today. Not from Gilead, not from anyone. The dominant long-acting approach remains ViiV's injectable regimen, and even that faces real-world challenges: cost, clinic infrastructure requirements, injection site reactions, and the logistics of keeping patients on schedule.

Gilead's WONDERS-2 failure doesn't close the door on weekly oral HIV treatment forever. But it does remind the field that "long-acting" and "oral" remain an exceptionally difficult pairing in antiretroviral development. The body processes oral drugs differently than injectables, and maintaining safe, effective concentrations over extended periods without accumulating toxicity is a tightrope walk.

For Gilead, the path forward runs through its remaining combinations, particularly the Merck-partnered islatravir/lenacapavir weekly pill and the expanding injectable portfolio. The $20.8 billion HIV franchise gives the company enormous financial cushion to absorb a setback like this.

But somewhere in that Gilead boardroom, someone is staring at a whiteboard where "weekly oral pill" just got crossed out. And next to it, "once-yearly injection" is circled in red. The future of HIV treatment is still long-acting. It just might not come in a bottle.

The $15 Billion Question Hanging Over Biotech's Future

The White House wants to cut $15.8 billion from HHS, including a $5 billion hit to NIH. Congress has killed proposals like this before, but the uncertainty alone is already doing damage to America's biotech pipeline.